Autopsy report · NCT06673069
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
Cause of deathFunding or business
“Sponsor decision to terminate study early. Decision not based on safety concerns.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 11 months before it stopped.
- 1 participant enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Alzheimer Disease; Down Syndrome
- Interventions
- ION269
- Participants
- 1
- Sites
- 6
- Countries
- Spain, United States
Trials that died the same way
- A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
“Sponsor decision to early terminate the study” - Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy
“Sponsor decision to close study early; not due to safety concerns” - Study of Ataluren (PTC124) in Hemophilia A and B
“Study was terminated early due to Sponsor decision and not reflective of adverse safety findings.” - Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
“Sponsor decided to terminate study early” - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
“The sponsor decided to terminate the study early”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.